Google DeepMind has unveiled an AI tool that its scientists claim could help unravel the mysteries of the human genome and transform our understanding of biology, accelerating scientific research and ultimately paving the way for new treatments for diseases.
The platform, called AlphaGenome Atlas, contains a “predictive map of every possible DNA letter change in the human genome,” the researchers said in a blog post published on Tuesday.
DNA is written in an alphabet of four chemical “letters” — usually shortened to A, C, G, and T — and the human genome contains roughly 3 billion letter pairs. Those letters contain the instructions that make life work, such as how, when, and where genes are switched on and off, and to what degree. Changes to individual letters can be harmless, contribute to ordinary differences between people, or play a role in disease – a major challenge is figuring out which changes matter and how. It is a tough task as there are roughly 9 billion potential single-letter substitutions.
Atlas contains predictions for how each of these 9 billion variants could affect the body at a molecular level, such as changing how much of a particular protein is produced. The researchers call it “the most comprehensive catalogue of how genetic mutations affect molecular biology.” Google says scientists can explore these predictions through a web portal, as a skill in its agentic development platform Antigravity, and through its AlphaGenome interface.
To help researchers sift through the billions of possibilities and focus on the mutations that warrant closer attention, Google is also releasing what it calls a Variant Impact Score (AVI), that draws on the company’s other models for predicting the effects of DNA changes. “Now, researchers can rapidly rank variants and interpret their molecular effects at the same time,” the company’s blog said.
The project builds on AlphaGenome, an AI model DeepMind unveiled last year to help scientists identify the genetic drivers of disease, as well as AlphaMissence, an earlier tool focused on predicting which small mutations might alter proteins. Atlas goes much further, extending predictions across the genome, including the vast majority of stretches that do not directly code for proteins, but can instead control how genes behave.
In a press briefing, Ziga Avsec, DeepMind’s genomics lead, acknowledged that the underlying model — AlphaGenome — had already been released, but said turning its capabilities into a genome-wide catalog took time. “Basically it took us some time to really precompute and also analyze this many variants because the space is so big,” he said.
AlphaGenome was trained using public databases of human and mouse genomes, allowing it to learn patterns between DNA changes and biological processes. Applying those predictions to billions of possible variants produced a massive dataset that Google says is roughly 1 petabyte in size.
The company says it is making Atlas available to researchers for noncommercial use through its website starting today, and for commercial use on Google Cloud “soon.”
